Your browser doesn't support javascript.
loading
Seroprevalence of Protective Antibodies Against Influenza and the Reduction of the Influenza Incidence Rate: An Annual Repeated Cross-Sectional Study From 2014 to 2019.
Guiomar, Raquel; Pereira da Silva, Susana; Costa, Inês; Conde, Patricia; Cristóvão, Paula; Rodrigues, Ana Paula; Fernandes, Aida; Dias, Ana Paula; Couto, Ana Rita; Ramos, Angélica; Moita, Carina; Rodrigues, Carina; Vale, Fátima; Caldeira, Filomena; Bruges Armas, Jácome; Pereira-Vaz, João; Alves, José; Freitas, Ludivina; Martins, Luis; Milho, Luís; Mota-Vieira, Luisa; Lopes, Lurdes; Freitas, Margarida; Pessanha, Maria Ana; Correia, Maria; Marques, Maria Helena; Cardoso, Maria João; Peres, Maria João; Cunha, Mário; Amantegui, Patricia; Mota, Paula; Lopes, Paulo; Pereira, Paulo; Viseu, Regina; Cabral, Rita; Côrte-Real, Rita; Almeida, Sofia; Soares, Vânia; Mansinho, Kamal; Hungnes, Olav; Nunes, Baltazar.
Afiliación
  • Guiomar R; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal.
  • Pereira da Silva S; Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal.
  • Costa I; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal.
  • Conde P; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal.
  • Cristóvão P; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal.
  • Rodrigues AP; Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal.
  • Fernandes A; Laboratório de Saúde Pública Dr.ª Laura Ayres, Faro, Portugal.
  • Dias AP; Centro Hospitalar de Lisboa Ocidental, E. P. E., Lisbon, Portugal.
  • Couto AR; Hospital de Santo Espírito da Ilha Terceira, E. P. E.R., Angra do Heroísmo, Portugal.
  • Ramos A; Centro Hospitalar Universitário de São João, E. P. E., Porto, Portugal.
  • Moita C; EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
  • Rodrigues C; Unidade Local de Saúde da Guarda, E. P. E., Guarda, Portugal.
  • Vale F; Hospital do Espírito Santo de Évora, E. P. E., Évora, Portugal.
  • Caldeira F; Unidade Local de Saúde da Guarda, E. P. E., Guarda, Portugal.
  • Bruges Armas J; Hospital do Espírito Santo de Évora, E. P. E., Évora, Portugal.
  • Pereira-Vaz J; Hospital de Santo Espírito da Ilha Terceira, E. P. E.R., Angra do Heroísmo, Portugal.
  • Alves J; Centro Hospitalar e Universitário de Coimbra, E. P. E., Coimbra, Portugal.
  • Freitas L; Hospital Central e Universitário da Madeira, Funchal, Portugal.
  • Martins L; Hospital Central e Universitário da Madeira, Funchal, Portugal.
  • Milho L; Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P. E., Lisbon, Portugal.
  • Mota-Vieira L; Laboratório de Saúde Pública Dr.ª Laura Ayres, Faro, Portugal.
  • Lopes L; Hospital do Divino Espirito Santo de Ponta Delgada, E. P. E. R., Ponta Delgada, Portugal.
  • Freitas M; Centro Hospitalar e Universitário de Lisboa Central, E. P. E., Lisbon, Portugal.
  • Pessanha MA; Hospital da Senhora da Oliveira Guimarães, E. P. E., Guimarães, Portugal.
  • Correia M; Centro Hospitalar de Lisboa Ocidental, E. P. E., Lisbon, Portugal.
  • Marques MH; Centro Hospitalar e Universitário de Coimbra, E. P. E., Coimbra, Portugal.
  • Cardoso MJ; Centro Hospitalar Universitário do Porto, E. P. E., Porto, Portugal.
  • Peres MJ; Centro Hospitalar Universitário de São João, E. P. E., Porto, Portugal.
  • Cunha M; Centro Hospitalar de Setúbal, E. P. E., Setúbal, Portugal.
  • Amantegui P; Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P. E., Lisbon, Portugal.
  • Mota P; Centro Hospitalar Universitário Cova da Beira, E. P. E., Covilhã, Portugal.
  • Lopes P; Hospital da Senhora da Oliveira Guimarães, E. P. E., Guimarães, Portugal.
  • Pereira P; Centro Hospitalar de Vila Nova de Gaia/Espinho, E. P. E., Vila Nova de Gaia, Portugal.
  • Viseu R; Centro Hospitalar Universitário do Porto, E. P. E., Porto, Portugal.
  • Cabral R; Centro Hospitalar de Setúbal, E. P. E., Setúbal, Portugal.
  • Côrte-Real R; Hospital do Divino Espirito Santo de Ponta Delgada, E. P. E. R., Ponta Delgada, Portugal.
  • Almeida S; Centro Hospitalar e Universitário de Lisboa Central, E. P. E., Lisbon, Portugal.
  • Soares V; Centro Hospitalar Universitário Cova da Beira, E. P. E., Covilhã, Portugal.
  • Mansinho K; Centro Hospitalar de Vila Nova de Gaia/Espinho, E. P. E., Vila Nova de Gaia, Portugal.
  • Hungnes O; Centro Hospitalar de Lisboa Ocidental, E. P. E., Lisbon, Portugal.
  • Nunes B; Norwegian National Influenza Centre, Norwegian Institute of Public Health, Oslo, Norway.
Influenza Other Respir Viruses ; 18(5): e13307, 2024 May.
Article en En | MEDLINE | ID: mdl-38798072
ABSTRACT

BACKGROUND:

Seroepidemiological studies provide estimates of population-level immunity, prevalence/incidence of infections, and evaluation of vaccination programs. We assessed the seroprevalence of protective antibodies against influenza and evaluated the correlation of seroprevalence with the cumulative annual influenza incidence rate.

METHODS:

We conducted an annual repeated cross-sectional seroepidemiological survey, during June-August, from 2014 to 2019, in Portugal. A total of 4326 sera from all age groups, sex, and regions was tested by hemagglutination inhibition assay. Seroprevalence and geometric mean titers (GMT) of protective antibodies against influenza were assessed by age group, sex, and vaccine status (65+ years old). The association between summer annual seroprevalence and the difference of influenza incidence rates between one season and the previous one was measured by Pearson correlation coefficient (r).

RESULTS:

Significant differences in seroprevalence of protective antibodies against influenza were observed in the population. Higher seroprevalence and GMT for A(H1N1)pdm09 and A(H3N2) were observed in children (5-14); influenza B seroprevalence in adults 65+ was 1.6-4.4 times than in children (0-4). Vaccinated participants (65+) showed significant higher seroprevalence/GMT for influenza. A strong negative and significant correlation was found between seroprevalence and ILI incidence rate for A(H1N1)pdm09 in children between 5 and 14 (r = -0.84; 95% CI, -0.98 to -0.07); a weak negative correlation was observed for A(H3N2) and B/Yamagata (r ≤ -0.1).

CONCLUSIONS:

The study provides new insight into the anti-influenza antibodies seroprevalence measured in summer on the ILI incidence rate in the next season and the need for adjusted preventive health care measures to prevent influenza infection and transmission.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gripe Humana / Anticuerpos Antivirales Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Asunto de la revista: VIROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Portugal

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gripe Humana / Anticuerpos Antivirales Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Asunto de la revista: VIROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Portugal